cancers Article Combinations of Radiotherapy with Vaccination and Immune Checkpoint Inhibition Differently Affect Primary and Abscopal Tumor Growth and the Tumor Microenvironment Michael Rückert 1 , Lisa Deloch 1 , Benjamin Frey 1 , Eberhard Schlücker 2, Rainer Fietkau 1 and Udo S. Gaipl 1,* 1 Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsklinikum Erlangen, 91054 Erlangen, Germany;
[email protected] (M.R.);
[email protected] (L.D.);
[email protected] (B.F.); rainer.fi
[email protected] (R.F.) 2 Institute of Process Machinery and Systems Engineering, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91058 Erlangen, Germany;
[email protected] * Correspondence:
[email protected]; Tel.: +49-(0)9131-85-44258 Simple Summary: Radiotherapy (RT) with higher single doses is capable of creating a beneficial immunological tumor microenvironment for additional immune therapies to trigger systemic anti- tumor immune responses. Here, we aimed to boost RT-induced immune responses with inactivated whole tumor cell vaccines generated with high hydrostatic pressure (HHP) and to break immuno- suppression by inhibition of suppressive immune checkpoint molecules, such as PD-1. Our results highlight that HHP vaccines act systemically to retard tumor growth, but only of previously irradiated tumors. In contrast, abscopal anti-tumor immune responses, namely those to non-irradiated tumors, Citation: Rückert, M.; Deloch, L.; are triggered by a combination of RT of not too many fractions plus anti-PD-1, being characterized Frey, B.; Schlücker, E.; Fietkau, R.; by the induction of distinct immune alterations in the primary and abscopal tumor, respectively. This Gaipl, U.S.